Head-to-head · free

Eli Lilly vs Lycia Therapeutics Inc.

LLY vs LYCA — return on capital, cash generation, margins and balance sheet side by side.

LLY

0 / 0

measures where LLY leads

LYCA

0 / 0

measures where LYCA leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureLLY · FY2025LYCA
Revenue$65.2B—
Net income$20.6B—
Revenue growth (yearly, multi-year)23.2%—
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC36.1%—
Return on equity101.4%—
Gross margin83.0%—
Operating margin45.6%—
Net debt / EBITDA1.25x—

Figures are as reported by each company; latest fiscal year shown.

Where Eli Lilly's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full LLY profile →

Where Lycia Therapeutics Inc.'s cash went

Not reported yet.

Full LYCA profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons